Table 1.
Baseline characteristics of patients and autologous cord blood units (n = 25)
| Patient characteristics | |
|---|---|
| Sex, no. (%) | |
| Female | 4 (16.0%) |
| Male | 21 (84.0%) |
| Age, years, median (range) | 4.62 (2.26–5.97) |
| Race, no. (%) | |
| White | 22 (88%) |
| Other | 3 (12%) |
| Ethnicity, no. (%) | |
| Hispanic | 2 (8%) |
| Not Hispanic | 23 (92%) |
| ADOS Severity Score, median (range) | 8 (6–10) |
| Nonverbal intelligence quotient, median (range) | 65 (22–123) |
| CGI‐S, no. (%) | |
| Barely evident | 4 (16.0%) |
| Moderate ASD symptoms | 3 (12.0%) |
| Moderately severe ASD | 10 (40.0%) |
| Severe ASD symptoms | 8 (32.0%) |
| Cord blood characteristics, median (range) | |
| Total cells infused, ×108 | 4.42 (1.53–12.28) |
| Cell dose infused, ×106/kg | 25.80 (9.97–80.80) |
| Viable CD34+ dose infused, ×105/kg | 0.3 (0.1–4.2) |
| CFU dose infused, /kg | 1,225.50 (85.50–4,620.00) |
Abbreviations: ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; CFU, colony‐forming units; CGI‐S, Clinical Global Impression‐Severity; TNCC, total nucleated cell count.